Patients with glioblastoma multiforme (GBM) have an average life expectancy of approximately 15 months. Recently, statins have emerged as a potential adjuvant cancer therapy due to their ability to inhibit cell proliferation and induce apoptosis in many types of cancer. The exact mechanisms that mediate the inhibitory actions of statins in cancer cells are largely unknown. The purpose of this proceeding paper is to discuss some of the known anticancer effects of statins, while focusing on GBM therapy that includes adjunct therapy of statins with chemotherapeutic agents.
AltwairgiAK. Statins are potential anticancerous agents (review). Oncol Rep2015;33:1019–39.doi:10.3892/or.2015.3741
2.
OstromQT, GittlemanH, FulopJ, . CBTRUS Statistical Report: Primary Brain and Central Nervous System Tumors Diagnosed in the United States in 2008-2012. Neuro Oncol2015;17 Suppl 4:iv1–iv62.doi:10.1093/neuonc/nov189
3.
Hombach-KlonischS, MehrpourM, ShojaeiS, . Glioblastoma and chemoresistance to alkylating agents: Involvement of apoptosis, autophagy, and unfolded protein response. Pharmacol Ther2018;184:13–41.doi:10.1016/j.pharmthera.2017.10.017
4.
YeganehB, WiechecE, AndeSR, . Targeting the mevalonate cascade as a new therapeutic approach in heart disease, cancer and pulmonary disease. Pharmacol Ther2014;143:87–110.doi:10.1016/j.pharmthera.2014.02.007
5.
NielsenSF, NordestgaardBG, BojesenSE. Statin use and reduced cancer-related mortality. N Engl J Med2012;367:1792–802.doi:10.1056/NEJMoa1201735
6.
GaistD, HallasJ, FriisS, . Statin use and survival following glioblastoma multiforme. Cancer Epidemiol2014;38:722–7.doi:10.1016/j.canep.2014.09.010
7.
AlizadehJ, ZekiAA, MirzaeiN, . Mevalonate cascade inhibition by simvastatin induces the intrinsic apoptosis pathway via depletion of isoprenoids in tumor cells. Sci Rep2017;7:44841.doi:10.1038/srep44841
8.
AltwairgiAK, AlghareebW, AlnajjarF, . Phase II study of atorvastatin in combination with radiotherapy and temozolomide In patients with glioblastoma (ART): interim analysis report Annals of Oncology. 2016;27.
9.
MatusewiczL, MeissnerJ, ToporkiewiczM, . The effect of statins on cancer cells-review. Tumour Biol2015;36:4889–904.doi:10.1007/s13277-015-3551-7
10.
Garcia-RuizC, MoralesA, Fernandez-ChecaJC. Statins and protein prenylation in cancer cell biology and therapy. Anticancer Agents Med Chem2012;12:303–15.doi:10.2174/187152012800228715
11.
CordleA, Koenigsknecht-TalbooJ, WilkinsonB, . Mechanisms of statin-mediated inhibition of small G-protein function. J Biol Chem2005;280:34202–9.doi:10.1074/jbc. M505268200
12.
OhB, KimTY, MinHJ, . Synergistic killing effect of imatinib and simvastatin on imatinib-resistant chronic myelogenous leukemia cells. Anticancer Drugs2013;24:20–31.doi:10.1097/CAD.0b013e32835a0fbd
13.
Tapia-PérezJH, KirchesE, MawrinC, . Cytotoxic effect of different statins and thiazolidinediones on malignant glioma cells. Cancer Chemother Pharmacol2011;67:1193–201.doi:10.1007/s00280-010-1535-2
14.
Young-XuY, JabbourS, GoldbergR, . Usefulness of statin drugs in protecting against atrial fibrillation in patients with coronary artery disease. Am J Cardiol2003;92:1379–83.doi:10.1016/j.amjcard.2003.08.040
15.
DurazzoAE, MachadoFS, IkeokaDT, . Reduction in cardiovascular events after vascular surgery with atorvastatin: a randomized trial. J Vasc Surg2004;39967–75.doi:10.1016/j.jvs.2004.01.004
16.
KertaiMD, BoersmaE, WesterhoutCM, . Association between long-term statin use and mortality after successful abdominal aortic aneurysm surgery. Am J Med2004;116:96–103.doi:10.1016/j.amjmed.2003.08.029
17.
LindenauerPK, PekowP, WangK, . Lipid-lowering therapy and in-hospital mortality following major noncardiac surgery. JAMA2004;291:2092–9.doi:10.1001/jama.291.17.2092
18.
RidkerPM, CannonCP, MorrowD, . C-reactive protein levels and outcomes after statin therapy. N Engl J Med Overseas Ed2005;352:20–8.doi:10.1056/NEJMoa042378
19.
SpampanatoC, De MariaS, SarnataroM, . Simvastatin inhibits cancer cell growth by inducing apoptosis correlated to activation of Bax and down-regulation of BCL-2 gene expression. Int J Oncol2012;40:935–41.doi:10.3892/ijo.2011.1273
20.
LewisKA, HolsteinSA, HohlRJ. Lovastatin alters the isoprenoid biosynthetic pathway in acute myelogenous leukemia cells in vivo. Leuk Res2005;29:527–33.doi:10.1016/j.leukres.2004.10.007
21.
KimWS, KimMM, ChoiHJ, . Phase II study of high-dose lovastatin in patients with advanced gastric adenocarcinoma. Invest New Drugs2001;19:81–3.doi:10.1023/A:1006481423298
22.
SivaprasadU, AbbasT, DuttaA. Differential efficacy of 3-hydroxy-3-methylglutaryl CoA reductase inhibitors on the cell cycle of prostate cancer cells. Mol Cancer Ther2006;5:2310–6.doi:10.1158/1535-7163.MCT-06-0175
23.
YuX, LuoY, ZhouY, . BRCA1 overexpression sensitizes cancer cells to lovastatin via regulation of cyclin D1-CDK4-p21WAF1/CIP1 pathway: analyses using a breast cancer cell line and tumoral xenograft model. Int J Oncol2008;33:555–63.
24.
Herrero-MartinG, López-RivasA. Statins activate a mitochondria-operated pathway of apoptosis in breast tumor cells by a mechanism regulated by ErbB2 and dependent on the prenylation of proteins. FEBS Lett2008;582:2589–94.doi:10.1016/j.febslet.2008.06.034
25.
ZhuY, CaseyPJ, KumarAP, . Deciphering the signaling networks underlying simvastatin-induced apoptosis in human cancer cells: evidence for non-canonical activation of RhoA and Rac1 GTPases. Cell Death Dis2013;4:e568.doi:10.1038/cddis.2013.103
26.
KochuparambilST, Al-HuseinB, GocA, . Anticancer efficacy of simvastatin on prostate cancer cells and tumor xenografts is associated with inhibition of Akt and reduced prostate-specific antigen expression. J Pharmacol Exp Ther2011;336:496–505.doi:10.1124/jpet.110.174870
27.
Ghosh-ChoudhuryN, MandalCC, Ghosh-ChoudhuryN, . Simvastatin induces derepression of PTEN expression via NFkappaB to inhibit breast cancer cell growth. Cell Signal2010;22:749–58.doi:10.1016/j.cellsig.2009.12.010
28.
JiangP, MukthavaramR, ChaoY, . In vitro and in vivo anticancer effects of mevalonate pathway modulation on human cancer cells. Br J Cancer2014;111:1562–71.doi:10.1038/bjc.2014.431
29.
LiuH, WangZ, LiY, . Simvastatin prevents proliferation and bone metastases of lung adenocarcinoma in vitro and in vivo. Neoplasma2013;60:240–6.doi:10.4149/neo_2013_032
30.
CollissonEA, KleerC, WuM, . Atorvastatin prevents RhoC isoprenylation, invasion, and metastasis in human melanoma cells. Mol Cancer Ther2003;2:941–8.
31.
FarinaHG, BublikDR, AlonsoDF, . Lovastatin alters cytoskeleton organization and inhibits experimental metastasis of mammary carcinoma cells. Clin Exp Metastasis2002;19:551–60.doi:10.1023/A:1020355621043
32.
HoriguchiA, SumitomoM, AsakumaJ, . 3-hydroxy-3-methylglutaryl-coenzyme a reductase inhibitor, fluvastatin, as a novel agent for prophylaxis of renal cancer metastasis. Clin Cancer Res2004;10:8648–55.doi:10.1158/1078-0432.CCR-04-1568
33.
ManuKA, ShanmugamMK, LiF, . Simvastatin sensitizes human gastric cancer xenograft in nude mice to capecitabine by suppressing nuclear factor-kappa B-regulated gene products. J Mol Med2014;92:267–76.doi:10.1007/s00109-013-1095-0
34.
HolsteinSA, HohlRJ. Synergistic interaction of lovastatin and paclitaxel in human cancer cells. Mol Cancer Ther2001;1:141–9.
35.
FeleszkoW, MłynarczukI, OlszewskaD, . Lovastatin potentiates antitumor activity of doxorubicin in murine melanoma via an apoptosis-dependent mechanism. Int J Cancer2002;100:111–8.doi:10.1002/ijc.10440
36.
RozadosVR, HinrichsenLI, McDonnellJ, . Lovastatin enhances in vitro radiation-induced apoptosis of rat B-cell lymphoma cells. J Exp Clin Cancer Res2005;24:55–61.
37.
MaceAG, GanttGA, SkacelM, . Statin therapy is associated with improved pathologic response to neoadjuvant chemoradiation in rectal cancer. Dis Colon Rectum2013;56:1217–27.doi:10.1097/DCR.0b013e3182a4b236
38.
KnoxJJ, SiuLL, ChenE, . A Phase I trial of prolonged administration of lovastatin in patients with recurrent or metastatic squamous cell carcinoma of the head and neck or of the cervix. Eur J Cancer2005;41:523–30.doi:10.1016/j.ejca.2004.12.013
39.
HindlerK, CleelandCS, RiveraE, . The role of statins in cancer therapy. Oncologist2006;11:306–15.doi:10.1634/theoncologist.11-3-306
40.
ChaeYK, YousafM, MalecekMK, . Statins as anti-cancer therapy; Can we translate preclinical and epidemiologic data into clinical benefit?Discov Med2015;20:413–27.
41.
BondyML, ScheurerME, MalmerB, . Brain tumor epidemiology: consensus from the Brain Tumor Epidemiology Consortium. Cancer2008;113(7 Suppl):1953–68.doi:10.1002/cncr.23741
42.
GaistD, AndersenL, HallasJ, . Use of statins and risk of glioma: a nationwide case-control study in Denmark. Br J Cancer2013;108:715–20.doi:10.1038/bjc.2012.536
43.
GjerstorffML. The Danish Cancer Registry. Scand J Public Health2011;39(7 Suppl):42–5.doi:10.1177/1403494810393562
44.
PengP, WeiW, LongC, . Atorvastatin augments temozolomide's efficacy in glioblastoma via prenylation-dependent inhibition of Ras signaling. Biochem Biophys Res Commun2017;489:293–8.doi:10.1016/j.bbrc.2017.05.147
45.
BilJ, ZapalaL, NowisD, . Statins potentiate cytostatic/cytotoxic activity of sorafenib but not sunitinib against tumor cell lines in vitro. Cancer Lett2010;288:57–67.doi:10.1016/j.canlet.2009.06.022
46.
CalabroA, TaiJ, AllenSL, . In-vitro synergism of m-TOR inhibitors, statins, and classical chemotherapy: potential implications in acute leukemia. Anticancer Drugs2008;19:705–12.doi:10.1097/CAD.0b013e328304ae19
47.
CemeusC, ZhaoTT, BarrettGM, . Lovastatin enhances gefitinib activity in glioblastoma cells irrespective of EGFRvIII and PTEN status. J Neurooncol2008;90:9–17.doi:10.1007/s11060-008-9627-0
48.
KhanzadaUK, PardoOE, MeierC, . Potent inhibition of small-cell lung cancer cell growth by simvastatin reveals selective functions of Ras isoforms in growth factor signalling. Oncogene2006;25:877–87.doi:10.1038/sj.onc.1209117
49.
KozarK, KaminskiR, LegatM, . Cerivastatin demonstrates enhanced antitumor activity against human breast cancer cell lines when used in combination with doxorubicin or cisplatin. Int J Oncol2004;24:1149–57.
50.
MartirosyanA, ClendeningJW, GoardCA, . Lovastatin induces apoptosis of ovarian cancer cells and synergizes with doxorubicin: potential therapeutic relevance. BMC Cancer2010;10:103.doi:10.1186/1471-2407-10-103
51.
RoudierE, MistafaO, SteniusU. Statins induce mammalian target of rapamycin (mTOR)-mediated inhibition of Akt signaling and sensitize p53-deficient cells to cytostatic drugs. Mol Cancer Ther2006;5:2706–15.doi:10.1158/1535-7163.MCT-06-0352
52.
StirewaltDL, AppelbaumFR, WillmanCL, . Mevastatin can increase toxicity in primary AMLs exposed to standard therapeutic agents, but statin efficacy is not simply associated with ras hotspot mutations or overexpression. Leuk Res2003;27:133–45.doi:10.1016/S0145-2126(02)00085-1
53.
YongjunY, ShuyunH, LeiC, . Atorvastatin suppresses glioma invasion and migration by reducing microglial MT1-MMP expression. J Neuroimmunol2013;260(1-2):1–8.doi:10.1016/j.jneuroim.2013.04.020
54.
ChangYL, HuangLC, ChenYC, . The synergistic effects of valproic acid and fluvastatin on apoptosis induction in glioblastoma multiforme cell lines. Int J Biochem Cell Biol2017;92:155–63.doi:10.1016/j.biocel.2017.10.003
55.
YanaeM, TsubakiM, SatouT, . Statin-induced apoptosis via the suppression of ERK1/2 and Akt activation by inhibition of the geranylgeranyl-pyrophosphate biosynthesis in glioblastoma. J Exp Clin Cancer Res2011;30:74–81.doi:10.1186/1756-9966-30-74
56.
StuppR, MasonWP, van den BentMJ, . Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med2005;352:987–96.doi:10.1056/NEJMoa043330
57.
ZhangWB, WangZ, ShuF, . Activation of AMP-activated protein kinase by temozolomide contributes to apoptosis in glioblastoma cells via p53 activation and mTORC1 inhibition. J Biol Chem2010;285:40461–71.doi:10.1074/jbc. M110.164046
RoosWP, BatistaLF, NaumannSC, . Apoptosis in malignant glioma cells triggered by the temozolomide-induced DNA lesion O6-methylguanine. Oncogene2007;26:186–97.doi:10.1038/sj.onc.1209785
60.
WeatherbeeJL, KrausJL, RossAH. ER stress in temozolomide-treated glioblastomas interferes with DNA repair and induces apoptosis. Oncotarget2016;7:43820–34.doi:10.18632/oncotarget.9907
61.
PalmerAC, SorgerPK. Combination cancer therapy can confer benefit via patient-to-patient variability without drug additivity or synergy. Cell2017;1711678–91.doi:10.1016/j.cell.2017.11.009
62.
DoroshowJH, SimonRM. On the design of combination cancer therapy. Cell2017;171:1476–8.doi:10.1016/j.cell.2017.11.035
63.
MinnAJ, WherryEJ. Combination cancer therapies with immune checkpoint blockade: Convergence on interferon signaling. Cell2016;165:272–5.doi:10.1016/j.cell.2016.03.031
64.
SharmaP, AllisonJP. Immune checkpoint targeting in cancer therapy: toward combination strategies with curative potential. Cell2015;161:205–14.doi:10.1016/j.cell.2015.03.030
65.
WangCY, LiuPY, LiaoJK. Pleiotropic effects of statin therapy: molecular mechanisms and clinical results. Trends Mol Med2008;14:37–44.doi:10.1016/j.molmed.2007.11.004
66.
LikusW, SiemianowiczK, BieńkK, . Could drugs inhibiting the mevalonate pathway also target cancer stem cells?Drug Resist Updat2016;25:13–25.doi:10.1016/j.drup.2016.02.001
67.
OlivieriF, MazzantiI, AbbatecolaAM, . Telomere/Telomerase system: a new target of statins pleiotropic effect?Curr Vasc Pharmacol2012;10:216–24.doi:10.2174/157016112799305076
68.
GhavamiS, MutaweMM, HauffK, . Statin-triggered cell death in primary human lung mesenchymal cells involves p53-PUMA and release of Smac and Omi but not cytochrome c. Biochim Biophys Acta1803;2010:452–67.
69.
JangHJ, HongEM, ParkSW, . Statin induces apoptosis of human colon cancer cells and downregulation of insulin-like growth factor 1 receptor via proapoptotic ERK activation. Oncol Lett2016;12:250–6.doi:10.3892/ol.2016.4569
70.
SwansonKM, HohlRJ. Anti-cancer therapy: targeting the mevalonate pathway. Curr Cancer Drug Targets2006;6:15–37.doi:10.2174/156800906775471743
71.
GhavamiS, YeganehB, StelmackGL, . Apoptosis, autophagy and ER stress in mevalonate cascade inhibition-induced cell death of human atrial fibroblasts. Cell Death Dis2012;3:e330.doi:10.1038/cddis.2012.61
72.
LawsonCD, RidleyAJ. Rho GTPase signaling complexes in cell migration and invasion. J Cell Biol2018;217:447–57.doi:10.1083/jcb.201612069
73.
KazanietzMG, CalocaMJ. THe rac GTPase in cancer: from old concepts to new paradigms. Cancer Res2017;77:5445–51.doi:10.1158/0008-5472.CAN-17-1456
74.
MatznoS, YasudaS, JumanS, . Statin-induced apoptosis linked with membrane farnesylated Ras small G protein depletion, rather than geranylated Rho protein. J Pharm Pharmacol2005;57:1475–84.doi:10.1211/jpp.57.11.0014
75.
TsubakiM, FujiwaraD, TakedaT, . The sensitivity of head and neck carcinoma cells to statins is related to the expression of their Ras expression status, and statin-induced apoptosis is mediated via suppression of the Ras/ERK and Ras/mTOR pathways. Clin Exp Pharmacol Physiol2017;44:222–34.doi:10.1111/1440-1681.12690
76.
ZandvakiliI, LinY, MorrisJC, . Rho GTPases: Anti- or pro-neoplastic targets?Oncogene2017;36:3213–22.doi:10.1038/onc.2016.473
77.
ShojaeiS, AlizadehJ, ThliverisJ, . Inhibition of autophagy by mevalonate pathway inhibitors, a new therapeutic approach to sensitize glioblastoma cells to temozolomide induced apoptosis. FASEB Jounral2018;32 533.41.
78.
GarwoodER, KumarAS, BaehnerFL, . Fluvastatin reduces proliferation and increases apoptosis in women with high grade breast cancer. Breast Cancer Res Treat2010;119:137–44.doi:10.1007/s10549-009-0507-x
79.
HanJY, LimKY, YuSY, SyY, . A phase 2 study of irinotecan, cisplatin, and simvastatin for untreated extensive-disease small cell lung cancer. Cancer2011;117:2178–85.doi:10.1002/cncr.25790
80.
SecklMJ, OttensmeierCH, CullenM, . Multicenter, Phase III, Randomized, Double-Blind, Placebo-Controlled Trial of pravastatin added to first-line standard chemotherapy in small-cell lung cancer (LUNGSTAR). J Clin Oncol2017;35:1506–14.doi:10.1200/JCO.2016.69.7391
81.
AllottEH, HowardLE, VidalAC, . Statin Use, Serum Lipids, and Prostate inflammation in men with a negative prostate biopsy: results from the REDUCE trial. Cancer Prev Res2017;10:319–26.doi:10.1158/1940-6207.CAPR-17-0019
82.
El-HamamsyM, ElwakilH, SaadAS, . A randomized controlled open-label pilot study of simvastatin addition to whole-brain radiation therapy in patients with brain metastases. Oncol Res2016;24:521–8.doi:10.3727/096504016X14719078133528
83.
KarpI, BehlouliH, LelorierJ, . Statins and cancer risk. Am J Med2008;121:302–9.doi:10.1016/j.amjmed.2007.12.011
